Interv Akut Kardiol. 2016;15(4):183-186 | DOI: 10.36290/kar.2016.036

Rivaroxaban - 4 year experience in the treatment of deep vein thrombosis

Petr Dulíček
IV. interní hematologická klinika FN a LF v Hradci Králové

Venous thromboembolism is a serious and frequent disease. It is dangerous not only due to the risk of fatal pulmonary embolism, but

also due to the late consequences. There is a big progress in the management of the disease in recent years because of the availability

of new anticoagulants. We present more than 4 years of our experience with therapy of venous thromboembolism with rivaroxaban.

Keywords: venous thromboembolism, home therapy, rivaroxaban

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P. Rivaroxaban - 4 year experience in the treatment of deep vein thrombosis. Interv Akut Kardiol. 2016;15(4):183-186. doi: 10.36290/kar.2016.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nordsrtöm M, Lindblad B, Bergvist D, et al. A prospective study of the incidence of deep vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155-160. Go to original source...
    2. Heit JA. Venous thromboembolism, disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-1617. Go to original source...
    3. Nicolaides A, Fareed J, Kakkar AJ, et al. Prevention and treatment of venous thrombembolism: International Consensus Statement (guidelines according to scientific evidence). Clin Appl Thromb Hemost 2013; 19: 116. Go to original source...
    4. Casey ET, Murad MH, Zumaeta-Garcia M, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55: 1463. Go to original source...
    5. Mewissen MW, et al. Catheter - directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology 1999. Go to original source...
    6. Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. Br Med J 2012; 345: e7498. Go to original source... Go to PubMed...
    7. SPC přípravku Xarelto, http://www.ema.europa.eu.
    8. Abrams PJ, Emerson CR. Rivaroxaban, a novel direct oral anti Xa inhibitor. Pharmacotherapy2009; 29: 167-181. Go to original source... Go to PubMed...
    9. Bauersachs R, Berkowitz SD, Brenner B, et al. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510. Go to original source...
    10. Büller HR, Prins MH, Lensin AW, et al., for EINSTEIN-PE investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-1297. Go to original source...
    11. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovascular Ther 2011; 9(7): 841-844. Go to original source...
    12. Ageno W, Mantovami W, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; Jan; 3(1): 12-21. Go to original source...
    13. Limone BL, Hernandez AV, Michalak D, et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res. 2013; 13: 420-426. Go to original source...
    14. Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. Circulation 2011; 123: 664. Go to original source...
    15. Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): e419S-494S. Go to original source...
    16. Sternitzky R, Hochauf S, Schellong SM. Secondary prophylaxis of venous thromboembolism. Haemostaseologie 2007; 27: 32-40. Go to original source...
    17. Carrier M, Rodger MA, Wells PS, et al. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 1119. Go to original source... Go to PubMed...
    18. Bagoun T, Palmer CR, Luddington R, et al. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Tromb Haemost 2008; 6(4): 577-582. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.